Posted by Bloomberg
CVS-Aetna Deal May Hinge on Antitrust Approach Under Trump
By Robert Langreth, David McLaughlin & Zachary Tracer
CVS Health’s US$67.5 billion takeover of Aetna will test the Trump administration’s approach to far-reaching corporate takeovers, just weeks after the US government sued to block a major telecommunications merger.
The health-care deal unveiled Sunday would create an industry giant with over US$240 billion in annual sales with a hand in insurance, prescription drug plan administration, retail pharmacies and corner clinics. The companies said the combination will save US$750 million in costs and bring consumers better, more efficient health care.
In the past, deals combining companies up and down a chain of business — such as a supplier and a distributor — have been viewed as posing less anticompetitive risk than combinations of direct rivals. Last month, however, the Justice Department sued to block just such a “vertical” merger between AT&T and Time Warner, saying it would harm consumers and limit their media content options.
Featured News
Alaska Airlines’ Hawaiian Acquisition Faces Antitrust Scrutiny
Dec 6, 2023 by
CPI
Ulmer & Greensfelder Merge to Form UB Greensfelder
Dec 6, 2023 by
CPI
Apple’s iMessage May Be Exempt from New EU Regulations
Dec 6, 2023 by
CPI
UK Watchdog Warns Firms on AI Privacy Compliance
Dec 6, 2023 by
CPI
FTC Mounts Second Challenge to Microsoft’s Activision Buy Despite Closed Deal
Dec 6, 2023 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Horizontal Competition: Mergers, Innovation & New Guidelines
Nov 30, 2023 by
CPI
Innovation in Merger Control
Nov 30, 2023 by
CPI
Making Sense of EU Merger Control: The Need for Limiting Principles
Nov 30, 2023 by
CPI
Sustainability Agreements in the EU: New Paths to Competition Law Compliance
Nov 30, 2023 by
CPI
Merger Control and Sustainability: A New Dawn or Nothing New Under the Sun?
Nov 30, 2023 by
CPI